Factors Associated with Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: an RTOG Analysis

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2008 Jun 19

PMID 18559875

Citations 441

Authors

Mitchell Machtay

Jennifer Moughan

Andrew Trotti

Adam S Garden

Randal S Weber

Jay S Cooper

Arlene Forastiere

K Kian Ang

Affiliations

Soon will be listed here.

Abstract

Purpose: Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that are associated with and might predict severe late toxicity after CCRT.

Methods: Patients were analyzed from a subset of three previously reported Radiation Therapy Oncology Group (RTOG) trials of CCRT for locally advanced SCCHN (RTOG 91-11, 97-03, and 99-14). Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube >or= 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years. Case-control analysis was performed, with a multivariable logistic regression model that included pretreatment and treatment potential factors.

Results: A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity. On multivariable analysis, significant variables correlated with the development of severe late toxicity were older age (odds ratio 1.05 per year; P = .001); advanced T stage (odds ratio, 3.07; P = .0036); larynx/hypopharynx primary site (odds ratio, 4.17; P = .0041); and neck dissection after CRT (odds ratio, 2.39; P = .018).

Conclusion: Severe late toxicity after CCRT is common. Older age, advanced T-stage, and larynx/hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was associated with an increased risk of these complications.

Citing Articles

Comparison of the Effect of Weekly Cisplatin Versus Three Weekly Cisplatin in Concurrent Chemoradiotherapy of Head and Neck Cancer: A Pilot Study.

Chaturvedi A, Sehrawat A, Mopidevi T, Parthasarthy K, Gupta D, Singh A Indian J Otolaryngol Head Neck Surg. 2025; 77(1):356-370.

PMID: 40070996 PMC: 11890838. DOI: 10.1007/s12070-024-05190-w.

Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial.

Rosenberg A, Juloori A, Jelinek M, Agrawal N, Cursio J, Cipriani N JAMA Oncol. 2025; .

PMID: 40048190 PMC: 11886870. DOI: 10.1001/jamaoncol.2025.0081.

Safety and efficacy of mecapegfilgrastim in preventing neutropenia in patients with head and neck cancer: a multicenter, prospective, observational, real-world study.

Cheng G, Chen Y, Xu N, Mao C, Zhang N, Chen M Transl Cancer Res. 2025; 13(12):6895-6904.

PMID: 39816534 PMC: 11730191. DOI: 10.21037/tcr-24-2035.

Gurizzan C, Cinquini M, Legramandi L, Resteghini C, Siano M, Bergamini C Ther Adv Med Oncol. 2025; 17():17588359241288251.

PMID: 39801611 PMC: 11724409. DOI: 10.1177/17588359241288251.

DNA double-strand break repair capacity and normal tissue toxicity induced by radiotherapy.

Nishibuchi I, Tashiro S J Radiat Res. 2024; 65(Supplement_1):i52-i56.

PMID: 39679883 PMC: 11647926. DOI: 10.1093/jrr/rrae081.

References

Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M . Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 50(5):1161-71. DOI: 10.1016/s0360-3016(01)01544-9. View

Feng F, Kim H, Lyden T, Haxer M, Feng M, Worden F . Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys. 2007; 68(5):1289-98. DOI: 10.1016/j.ijrobp.2007.02.049. View

Bourhis J, Le Maitre A, Baujat B, Audry H, Pignon J . Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol. 2007; 19(3):188-94. DOI: 10.1097/CCO.0b013e3280f01010. View

Bentzen S, Vaeth M, Pedersen D, Overgaard J . Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now!. Int J Radiat Oncol Biol Phys. 1995; 32(5):1531-4. DOI: 10.1016/0360-3016(95)00262-W. View

Greenberger J, Epperly M . Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. In Vivo. 2007; 21(2):141-6. View

Kouvaris J, Kouloulias V, Vlahos L . Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007; 12(6):738-47. DOI: 10.1634/theoncologist.12-6-738. View

Dornfeld K, Simmons J, Karnell L, Karnell M, Funk G, Yao M . Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life. Int J Radiat Oncol Biol Phys. 2007; 68(3):750-7. DOI: 10.1016/j.ijrobp.2007.01.047. View

Wendt T, Grabenbauer G, Rodel C, Thiel H, Aydin H, Rohloff R . Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998; 16(4):1318-24. DOI: 10.1200/JCO.1998.16.4.1318. View

Henk J . Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol (R Coll Radiol). 1997; 9(5):308-12. DOI: 10.1016/s0936-6555(05)80064-0. View

10.

Pignon J, Bourhis J, Domenge C, Designe L . Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355(9208):949-55. View

11.

Shiley S, Hargunani C, Skoner J, Holland J, Wax M . Swallowing function after chemoradiation for advanced stage oropharyngeal cancer. Otolaryngol Head Neck Surg. 2006; 134(3):455-9. DOI: 10.1016/j.otohns.2005.10.054. View

12.

Bensadoun R, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A . French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2005; 64(4):983-94. DOI: 10.1016/j.ijrobp.2005.09.041. View

13.

Brizel D, Albers M, Fisher S, Scher R, Richtsmeier W, Hars V . Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338(25):1798-804. DOI: 10.1056/NEJM199806183382503. View

14.

Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P . Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999; 91(24):2081-6. DOI: 10.1093/jnci/91.24.2081. View

15.

Adelstein D, Lavertu P, Saxton J, Secic M, Wood B, Wanamaker J . Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000; 88(4):876-83. DOI: 10.1002/(sici)1097-0142(20000215)88:4<876::aid-cncr19>3.0.co;2-y. View

16.

Stuben G, Thews O, Pottgen C, Knuhmann K, Vaupel P, Stuschke M . Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol. 2001; 127(6):346-50. DOI: 10.1007/s004320000215. View

17.

Rosenthal D, Lewin J, Eisbruch A . Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol. 2006; 24(17):2636-43. DOI: 10.1200/JCO.2006.06.0079. View

18.

Forastiere A, Goepfert H, Maor M, Pajak T, Weber R, Morrison W . Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22):2091-8. DOI: 10.1056/NEJMoa031317. View

19.

Ang K, Harris J, Garden A, Trotti A, Jones C, Carrascosa L . Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005; 23(13):3008-15. DOI: 10.1200/JCO.2005.12.060. View

20.

Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A . Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2002; 55(1):78-92. DOI: 10.1016/s0360-3016(02)03792-6. View